Skip to content

US · CELC · BIOTECHNOLOGY

Celcuity Inc. (CELC) intrinsic value and stock valuation

$53.35as of 2026-11-21 · Mkt cap 4.53B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Celcuity Inc. DCF and intrinsic value

InvestorsCraft values CELC with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CELC’s statements →

Celcuity Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Minneapolis, MN 55441 celcuity.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$0.00
20152025
Net income
-$-177.04M
20152025
Free cash flow
-$-153.53M
20152025
Total equity
$100.6M+53.8% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-172.19M-$-113.27M-$-66.23M-$-39.39M-$-28.36M
Net income-$-177.04M-$-111.78M-$-63.78M-$-40.37M-$-29.61M
EPSd-$-3.37M-$-2.83M-$-2.69M-$-2.62M-$-2.21M
Operating cash flow-$-153.28M-$-83.47M-$-53.81M-$-36.01M-$-20.31M
Capital expenditure-$-250K-$-250K-$-100K-$-160K-$-80K
Free cash flow-$-153.53M-$-83.72M-$-53.91M-$-36.17M-$-20.39M
Total assets$466.6M$245.1M$191.2M$175.7M$85.9M
Total debt$195.4M$98M$37.5M$35.2M$14.9M
Net debt$29.7M$75.4M$6.78M$10.7M-$-69.4M
Total equity$100.6M$115.6M$139.8M$133.8M$68.7M
Cash and short-term investments$441.5M$235.1M$180.6M$168.6M$84.3M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$170K$0.00$0.00$0.00$0.00
Gross profit-$-170K$0.00$0.00$0.00$0.00
Research and development expenses$145M$104.2M$60.6M$35.3M$25.8M
Selling, general and administrative expenses$27.2M$9.06M$5.64M$4.38M$2.6M
Other expenses$0.00$0.00$0.00-$-280K$0.00
Operating expenses$172.2M$113.3M$66.2M$39.4M$28.4M
Cost and expenses$172.2M$113.3M$66.2M$39.4M$28.4M
Interest income$12.3M$11.8M$7.78M$1.13M$10K
Interest expense$17.2M$10.3M$5.33M$2.11M$1.26M
Depreciation and amortization$170K$130K$140K$210K$300K
Ebitda-$-159.73M-$-101.37M-$-58.31M-$-38.05M-$-28.04M
Operating income-$-172.19M-$-113.27M-$-66.23M-$-39.39M-$-28.36M
Total other income/expenses, net-$-4.85M$1.49M$2.45M-$-980K-$-1.25M
Income before tax-$-177.04M-$-111.78M-$-63.78M-$-40.37M-$-29.61M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-177.04M-$-111.78M-$-63.78M-$-40.37M-$-29.61M
Weighted average shares outstanding$52.5M$39.5M$23.7M$15.4M$13.4M
Weighted average diluted shares outstanding$52.5M$39.5M$23.7M$15.4M$13.4M
Balance sheet
20252024202320222021
Cash and short-term investments$441.5M$235.1M$180.6M$168.6M$84.3M
Net receivables$0.00$1.6M$810K$200K$300K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$465.7M$244.6M$190.6M$175.2M$85.4M
Property, plant and equipment, net$550K$550K$630K$510K$550K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$900K$550K$630K$540K$550K
Total assets$466.6M$245.1M$191.2M$175.7M$85.9M
Accounts payable$6.41M$9.37M$5.08M$2.63M$1.51M
Short-term debt$50K$170K$180K$190K$200K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$44.2M$31.7M$14.2M$6.88M$2.51M
Long-term debt$195.3M$97.8M$37.3M$35M$14.7M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$321.9M$97.8M$37.3M$35M$14.7M
Capital lease obligations$0.00$230K$410K$60K$260K
Total liabilities$366M$129.5M$51.5M$41.9M$17.2M
Common stock$50K$40K$30K$20K$10K
Retained earnings-$-448.9M-$-271.86M-$-160.08M-$-96.3M-$-55.93M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$100.6M$115.6M$139.8M$133.8M$68.7M
Total investments$275.8M$212.6M$149.9M$144M$0.00
Total debt$195.4M$98M$37.5M$35.2M$14.9M
Net debt$29.7M$75.4M$6.78M$10.7M-$-69.4M
Cash flow statement
20252024202320222021
Net income-$-177.04M-$-111.78M-$-63.78M-$-40.37M-$-29.61M
Depreciation and amortization$170K$130K$140K$210K$300K
Stock-based compensation$21.4M$6.99M$4.9M$4.64M$2.61M
Change in working capital-$-2.65M$18.4M$3.86M-$-1.19M$820K
Accounts receivable$0.00$0.00$0.00$100K-$-110K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-3.04M$4.32M$2.43M$1.08M$1.31M
Net cash provided by operating activities-$-153.28M-$-83.47M-$-53.81M-$-36.01M-$-20.31M
Investments in property, plant and equipment-$-250K-$-250K-$-100K-$-160K-$-80K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-64.08M-$-63.07M-$-5.01M-$-144.03M-$-80K
Common stock issued$137.9M$63.6M$14.4M$100.5M$78.6M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$360.6M$138.4M$64.9M$120.3M$93M
Net change in cash$143.2M-$-8.15M$6.09M-$-59.71M$72.7M
Cash at end of period$165.7M$22.5M$30.7M$24.6M$84.3M
Operating cash flow-$-153.28M-$-83.47M-$-53.81M-$-36.01M-$-20.31M
Capital expenditure-$-250K-$-250K-$-100K-$-160K-$-80K
Free cash flow-$-153.53M-$-83.72M-$-53.91M-$-36.17M-$-20.39M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Celcuity Inc.

        Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

        CEO
        Brian F. Sullivan
        Employees
        155
        Beta
        0.16

        Explore

        Frequently asked questions

        What is the intrinsic value of Celcuity Inc. (CELC)?

        InvestorsCraft does not currently publish an intrinsic value for CELC. How the IC value is calculated.

        Is CELC undervalued?

        InvestorsCraft does not publish an undervaluation signal for CELC at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.